HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has announced the results of a groundbreaking study conducted in Japan, which underscores the technological advantages of its XTRAC® Excimer Laser over other UVB light sources, such as Excimer Light, for treating conditions like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. Published in the Journal of Nippon Medical School by researchers from Nippon Medical School, the study highlights the laser’s deeper penetration, greater activation of melanocyte lineage cells, and fewer side effects, which contribute to superior clinical outcomes.
Among its findings, the study emphasizes the precision and power of the XTRAC Excimer Laser, which features monochromatic coherent light with a high frequency of 400 Hz and remarkable irradiance. These attributes enable deeper penetration into hair follicles, heightened activation of melanocyte stem cells, and reduced epidermal side effects in comparison to Excimer Light treatments.
“This latest clinical study further validates the superiority of Strata Skin Sciences’ advanced technologies embedded in the XTRAC® Excimer Laser over other (less accurate, non-collimated, lower frequency and irradiation level) UVB light sources such as Excimer Light, reinforcing our commitment to delivering innovative and effective treatment solutions to patients worldwide,” said Dr. Dolev Rafaeli, President and CEO of STRATA Skin Sciences.
Key Findings
- Deeper Penetration into Hair Follicles:
The study shows that the XTRAC Excimer Laser penetrates significantly deeper into hair follicles than Excimer Light, which is critical for reaching melanocyte stem cells (McSCs) and driving effective re-pigmentation in patients with vitiligo. - Enhanced Melanocyte Activation:
The laser was shown to activate more melanocyte lineage cells, including TRP2-positive cells, which are crucial for melanin production. This leads to more effective re-pigmentation compared to other UVB light sources. - Reduced Side Effects:
By minimizing DNA damage and accelerating the removal of Cyclobutane Pyrimidine Dimers (CPDs), the XTRAC Laser reduces skin stress and improves patient safety. - Higher Efficiency:
With its high irradiance, the XTRAC can deliver therapeutic doses in significantly less time. For instance, it can administer a 1,000 mJ/cm² dose in just one second, compared to 20 seconds required by Excimer Light. This efficiency enhances patient comfort and treatment outcomes. - Superior Clinical Outcomes:
The study supports the laser’s ability to deliver faster re-pigmentation, fewer required treatment sessions, and better outcomes in cases where other methods, such as narrowband UVB or Excimer Light, have proven less effective.
STRATA’s Expanding Reach
The findings bolster STRATA’s global presence. Since its launch in Japan in 2019, over 100 XTRAC Excimer Laser devices have been placed in the country, including 24 installations in 2024 alone, replacing a significant number of the older VTRAC® Excimer Light devices. Globally, STRATA has surpassed 1,800 XTRAC devices installed in the U.S. and over 1,000 internationally.
“Our continued success in Japan—a highly advanced clinical environment—demonstrates the growing recognition of XTRAC’s benefits for patients with vitiligo, psoriasis, alopecia areata, and atopic dermatitis,” noted Dr. Rafaeli.
With hundreds of peer-reviewed studies supporting its Excimer Laser technology, STRATA Skin Sciences continues to lead advancements in dermatological treatments and improve outcomes for autoimmune skin conditions. This latest research further solidifies the XTRAC Laser’s role as a game-changer in precision dermatology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.